Altimmune’s Pemvidutide Shows Promising MASH Data at EASL 2026
Event summary
- Altimmune’s IMPACT Phase 2b trial data for pemvidutide in MASH selected as 'Best of EASL 2026'
- 48-week efficacy and safety results to be presented orally at EASL Congress 2026
- Late-breaker poster highlights digital pathology analysis of fibrosis regression at 24 weeks
- Additional posters focus on non-invasive tests and cardiovascular risk factors
The big picture
Altimmune’s presentation at EASL 2026 underscores the growing competition in the MASH treatment landscape, where pemvidutide’s dual glucagon/GLP-1 mechanism offers a differentiated approach. The selection of its data as 'Best of EASL' highlights the significance of its findings, potentially attracting more investor and partner interest. The broader industry is watching closely as MASH becomes a key focus area for biopharmaceutical innovation, with regulatory pathways and clinical outcomes shaping the next wave of therapeutic breakthroughs.
What we're watching
- Regulatory Momentum
- Whether Fast Track and Breakthrough Therapy Designations will accelerate pemvidutide’s approval path for MASH.
- Clinical Validation
- How the 48-week data compares to competitors in the MASH space and its potential impact on market positioning.
- Pipeline Expansion
- The progress of ongoing RECLAIM and RESTORE trials in AUD and ALD, respectively, and their implications for Altimmune’s diversified portfolio.
Related topics